The effects of bimatoprost on aqueous humor dynamics were quantified in monkey eyes. Uveoscleral outflow was measured by the anterior chamber perfusion method, using FITC-dextran. Total outflow facility was determined by the two-level constant pressure method. Aqueous flow was measured with a scanning ocular fluorophotometer. Uveoscleral outflow was 0.96±0.19 L min−1 in vehicle-treated eyes and 1.37±0.27 L min−1 (=6; <.05) in eyes that received bimatoprost 0.01% b.i.d. × 5 days. Bimatoprost had no effect on total outflow facility, which was 0.42±0.05 L min−1 at baseline and 0.42±0.04 L min−1 after bimatoprost treatment. Bimatoprost had no significant effect on aqueous humor flow. This study demonstrates that bimatoprost increases uveosclera...
Kenji Inoue,1 Minako Shiokawa,1 Takayuki Fujimoto,1 Goji Tomita21Inouye Eye Hospital, Tokyo, Japan; ...
BACKGROUND AND PURPOSE:The intraocular pressure (IOP)-lowering and side effects in response to diffe...
To evaluate the safety of two commercially available formulations of bimatoprost eye drops: 0.03 and...
The effects of bimatoprost on aqueous humor dynamics were quantified in monkey eyes. Uveoscleral out...
PurposeTo assess the intraocular pressure (IOP)-lowering effects of bimatoprost sustained-release im...
Purpose: To demonstrate the effects of bimatoprost on the optic nerve head (ONH) and peripapillary r...
Purpose: To determine the effects of the kappa opioid agonist, bremazocine (BRE), on intraocular pre...
PURPOSE. To assess the early effect of latanoprost on outflow facility and aqueous humor dynamics in...
WOS: 000225104800002PubMed: 15069567Purpose: To study the effect of bimatoprost 0.03% (Lumigan) on o...
Glaucoma is the second leading cause of irreversible blindness in the United States. It is character...
Abayomi B Ogundele, David Earnest, Marsha A McLaughlinAlcon Research, Limited, Fort Worth, TX, USAOb...
PURPOSE: To explore the ocular distribution of bimatoprost after intracameral administration of a bi...
PURPOSE: Intraocular pressure (IOP) is a major risk factor for glaucoma, and the only therapeutic in...
Objective: To evaluate the effects on intraocular pressure (IOP), pupillary diameter (PD), blepharos...
Purpose: This study examines the effects of 2 Rho kinase inhibitors on intraocular pressure (IOP) an...
Kenji Inoue,1 Minako Shiokawa,1 Takayuki Fujimoto,1 Goji Tomita21Inouye Eye Hospital, Tokyo, Japan; ...
BACKGROUND AND PURPOSE:The intraocular pressure (IOP)-lowering and side effects in response to diffe...
To evaluate the safety of two commercially available formulations of bimatoprost eye drops: 0.03 and...
The effects of bimatoprost on aqueous humor dynamics were quantified in monkey eyes. Uveoscleral out...
PurposeTo assess the intraocular pressure (IOP)-lowering effects of bimatoprost sustained-release im...
Purpose: To demonstrate the effects of bimatoprost on the optic nerve head (ONH) and peripapillary r...
Purpose: To determine the effects of the kappa opioid agonist, bremazocine (BRE), on intraocular pre...
PURPOSE. To assess the early effect of latanoprost on outflow facility and aqueous humor dynamics in...
WOS: 000225104800002PubMed: 15069567Purpose: To study the effect of bimatoprost 0.03% (Lumigan) on o...
Glaucoma is the second leading cause of irreversible blindness in the United States. It is character...
Abayomi B Ogundele, David Earnest, Marsha A McLaughlinAlcon Research, Limited, Fort Worth, TX, USAOb...
PURPOSE: To explore the ocular distribution of bimatoprost after intracameral administration of a bi...
PURPOSE: Intraocular pressure (IOP) is a major risk factor for glaucoma, and the only therapeutic in...
Objective: To evaluate the effects on intraocular pressure (IOP), pupillary diameter (PD), blepharos...
Purpose: This study examines the effects of 2 Rho kinase inhibitors on intraocular pressure (IOP) an...
Kenji Inoue,1 Minako Shiokawa,1 Takayuki Fujimoto,1 Goji Tomita21Inouye Eye Hospital, Tokyo, Japan; ...
BACKGROUND AND PURPOSE:The intraocular pressure (IOP)-lowering and side effects in response to diffe...
To evaluate the safety of two commercially available formulations of bimatoprost eye drops: 0.03 and...